Navigation Links
Biosimilars Market Entry Strategies - For Pharma Companies, Biosimilars Offer a Relatively Low Risk Growth Strategy
Date:12/26/2011

DALLAS, December 26, 2011 /PRNewswire/ --

ReportsnReports adds new market research report 'Biosimilars : Market Entry Strategies' to its store. This report provides an analysis of strategies employed by the top 50 pharma companies that are active or plan to enter the biosimilars sector in the future, together with an analysis of biosimilar deal trends among the top 50 pharma companies.

  • Of the companies analyzed, each of the eight generics companies ranked among the top 50 pharma companies have an active interest in biosimilars, reflecting the fact that such products have the opportunity to increase the profit margin of generics companies.
  • Many innovative pharma companies have also entered the biosimilars arena with further companies such as Boehringer Ingelheim showing signs of interest.
  • However, a number of companies such as AstraZeneca, Bayer, and Roche have stated that they have no plans to enter the biosimilars market, instead maintaining their innovative focus.


Study Comprehensive Table of Contents and Request a Sample for the report @  http://www.reportsnreports.com/reports/144201-biosimilars-market-entry-strategies.html

With sales for the top 50 pharma companies forecast to decline by 1.6% during 2010-16, many leading drugmakers are looking to expand into markets which offer long-term growth, limited competition, and are relatively low risk. Biosimilars is one such area, which has attracted both innovative biologics players and generics players alike.

Features and benefits

  • Insight into why pharma are tapping into the biosimilars market
  • Analysis of biosimilar deal trends among the top 50 pharma companies
  • Insight into the top 50 pharma companies active in biosimilars
  • Review of the top 50 pharma companies that plan to enter the biosimilars market in the near future
  • Summary of the top 50 pharma companies plan to avoid biosimilars

Your key questions answered

  • Understand how and why different corporate pharma companies are targeting biosimilars
  • Examine why some companies have opted not to enter this sector

Inquire Before Buying or get your copy of the report on Biosimilars Market Entry Strategies.

Find other newly published market research reports @ http://www.reportsnreports.com/latest-market-research.aspx.

About Us:

ReportsnReports.com is an online market research library of 135,000+ reports and in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers. Visit http://www.reportsnreports.com/ for more details.

Contact:
Priyank Tiwari
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-391-5441
sales@reportsandreports.com
Visit our Market Research Blog @ http://www.reportsnreportsblog.com/


'/>"/>
SOURCE ReportsnReports
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Leading Indian CRO Max Neeman International Expands in Response to Positive Biosimilars Market in India
2. Multi-therapy Drugs: Opportunities for Generics & Biosimilars
3. Reportlinker Adds Generic Growth Strategies - Manufacturers to Increase Focus on Super Generics and Biosimilars to Drive Revenues
4. Key Presentations Announced for Landmark Future of Biosimilars Event Co-Sponsored by DIA and FDLI, Co-Chaired by Merck and PAREXEL
5. Reportlinker Adds Global Biosimilars (Follow-on biologics) Market: An Analysis
6. Oncologists Will Be More Aggressive In Adopting Biosimilars Compared With Other Specialties
7. PAREXEL Consulting Thought Leaders Provide Insights Into U.S. Biosimilar Development and Monoclonal Biosimilars in Two New White Papers
8. Decision Resources Competitive Landscape Seminar Series: Biologics and Biosimilars on September 14, 2010 Will Help Pharmaceutical Companies Understand Market Opportunities for Biologics and Biosimilars
9. ReportsandReports: Biosimilars Series - Forecast Analysis Market Research Report
10. Orphan Drug Markets in Europe
11. Global Markets for Laser Systems, Components and Materials -- Focus on Asia-Pacific
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... and EDMONTON, Alberta , ... scientists and the University of Alberta in ... data in Nature,s partner journal, Schizophrenia 1 , ... predict instances of schizophrenia with 74% accuracy. This ... severity of specific symptoms in schizophrenia patients with ...
(Date:7/21/2017)... Did you know that PhRMA member companies invested $65.5 billion in ... brand medicines, generics and the supply chain account for 14 percent ... of this (7 percent)? Or that the United States ... investments in high-growth biopharmaceutical startups? ... The biopharmaceutical industry accounts ...
(Date:7/17/2017)... Fla. , July 17, 2017  MedX Holdings, ... branded medical testing, strengthening and rehabilitation equipment, today announced ... Machine Program. MedX is considered the gold standard for ... leader in specialized medical strengthening equipment. ... a lease with the physician or practice who prescribe ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... July 24, 2017 , ... ... effectively destroyed the construction site and threatened numerous homes and businesses nearby, causing ... article on NBCLosAngeles.com. Los Angeles Area consulting firm Fire Protection Group, Inc. ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... Axiad ... organizations, today announced it has partnered with WALLIX to expand its solution ... 800-171 . , There are a number of ways to address the authentication requirements ...
(Date:7/24/2017)... ... 24, 2017 , ... Puregraft, the global leader in the ... United States Patent Number 9,695,398 (the '398 patent) and South Korean Patent Number ... '324 patents cover methods and systems for optimizing fat grafts for current and ...
(Date:7/24/2017)... ... 2017 , ... A new report released today by FusionHealth, ... health care at scale, indicates record-breaking adherence results for the company’s obstructive sleep ... pressure (PAP) therapy, the most widely utilized treatment for OSA, typically range between ...
(Date:7/24/2017)... ... July 24, 2017 , ... Committed to eliminating ... enrolled over 100,000 children in their treatment program. Clubfoot is a pervasive problem ... where treatment is limited or non-existent. Without intervention, these children are destined to ...
Breaking Medicine News(10 mins):